For examples, a potential impact of CB1 on the inflammatory response associated with NASH has been suggested by experiments in obese rats, showing that CB1 antagonist rimonabant plays a hepatoprotective role in the treatment of obesity-associated liver diseases and related features of metabolic syndrome [23,24]. Here, CNR1 is linked to Obesity.